Alpha-tocopheryl succinate, an agent with in vivo anti-tumour activity, induces apoptosis by causing lysosomal instability

Print
Published on Thursday, 14 April 2016

Abstract

Certain vitamin E analogues, such as alpha-tocopheryl succinate (alpha-TOS), exhibit in vivo anti-tumour activity and, in vitro, induce apoptosis of cultured tumour cells.

In the present study we report that these effects may be explained, at least in part, by destabilization of lysosomal membranes. alpha-TOS, but not alpha-tocopheryl acetate or alpha-tocopherol (alpha-TOH), induced early lysosomal destabilization followed by apoptosis. Similar effects were observed with beta-TOS, whereas beta-TOH was inactive. Cathepsin D-deficient cells were more resistant to alpha-TOS than their normal counterparts, and featured delayed caspase activation.

Possible detergent and lysosomotropic effects of alpha- and beta-TOS were suggested by their haemolytic activity in an in vitro test and their release of beta-galactosidase from isolated lysosomes, whereas the non-succinylated analogues were inactive.

The pro-apoptotic activity of alpha-TOS was pH-dependent, being greater at lower pH, typical of the interstitium of solid tumours.

These findings indicate that lysosomal destabilization may partially or fully explain the induction of apoptosis in cultured cells by alpha-TOS and the mechanism whereby this agent exerts in vivo anti-tumour effects.

 



Download the complete article

 

About this publication.

 

See also:

- Solution of retinoids in vitamin E in the Di Bella Method biological multitherapy;

- Evaluation of the safety and efficacy of the first-line treatment with somatostatin combined with melatonin, retinoids, vitamin D3, and low doses of cyclophosphamide in 20 cases of breast cancer: a preliminary report;

- The Di Bella Method (DBM) improved survival, objective response and performance status in a retrospective observational clinical study on 122 cases of breast cancer;

- Complete objective response to biological therapy of plurifocal breast carcinoma;

- Cyclophosphamide plus Somatostatin, Bromocriptin, Retinoids, Melatonin and ACTH in the Treatment of Low-grade Non-Hodgkin’s Lymphomas at Advanced Stage: Results of a Phase II Trial;

- Relapse of High-Grade Non-Hodgkin’s Lymphoma After Autologous Stem Cell Transplantation: A Case Successfully Treated With Cyclophosphamide Plus Somatostatin, Bromocriptine, Melatonin, Retinoids, and ACTH;

- Low-grade Non-Hodgkin Lymphoma at Advanced Stage: A Case Successfully Treated With Cyclophosphamide Plus Somatostatin, Bromocriptine, Retinoids, and Melatonin;

- The Di Bella Method (DBM) improved survival, objective response and performance status in a retrospective observational clinical study on 55 cases of Lymphomas;

- Somatostatin, retinoids, melatonin, vitamin D, bromocriptine, and cyclophosphamide in advanced non-small-cell lung cancer patients with low performance status;

- Somatostatin, retinoids, melatonin, vitamin D, bromocriptine, and cyclophosphamide in chemotherapy-pretreated patients with advanced lung adenocarcinoma and low performance status.